First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

JOURNAL ARTICLE published February 2021 in The Lancet Oncology

Authors: Luis Paz-Ares | Tudor-Eliade Ciuleanu | Manuel Cobo | Michael Schenker | Bogdan Zurawski | Juliana Menezes | Eduardo Richardet | Jaafar Bennouna | Enriqueta Felip | Oscar Juan-Vidal | Aurelia Alexandru | Hiroshi Sakai | Alejo Lingua | Pamela Salman | Pierre-Jean Souquet | Pedro De Marchi | Claudio Martin | Maurice Pérol | Arnaud Scherpereel | Shun Lu | Thomas John | David P Carbone | Stephanie Meadows-Shropshire | Shruti Agrawal | Abderrahim Oukessou | Jinchun Yan | Martin Reck